摘要
为评析阿立哌唑对首发精神分裂症患者的治疗作用,选取2017年3月—2018年3月本院收治的68例首发精神分裂症患者,随机分为对照组和观察组,各34例。对照组采用利培酮治疗,观察组采用阿立哌唑治疗,以8周为一个疗程,观察疗程结束后,两组临床疗效,并监测两组不良反应情况。观察组精神分裂症治疗总有效率(94. 12%,32/34)显著高于对照组(73. 53%,25/34),差异具有统计学意义(P=0. 021,χ~2=4. 713)。观察组不良反应发生率(11. 76%,4/34)显著低于对照组(23. 53%,8/34),差异具有统计学意义(P=0. 022,χ~2=4. 389)。说明,首发精神分裂症患者应用阿立哌唑治疗,可有效控制精神病症状,疗效可靠,不良反应发生率低,值得推广借鉴。
In order to evaluate the therapeutic effect of aripiprazole on first-episode schizophrenia,68 first-episode schizophrenia patients admitted to our hospital from March 2017 to March 2018 were randomly divided into control group and observation group,34 cases in each group. The control group was treated with risperidone and the observation group was treated with aripiprazole for 8 weeks. After the end of the treatment,the clinical efficacy of the two groups was observed,and the adverse reactions of two groups were monitored. The total effective rate of schizophrenia treatment in the observation group( 94. 12%,32/34) was significantly lower than that in the control group( 73. 53%,25/34),the difference was statistically significant( P = 0. 021,χ~2= 4. 713). The incidence of adverse reactions in the observation group( 11. 76%) was significantly lower than that in the control group( 23. 53%). The difference was statistically significant( P = 0. 022,χ~2= 4. 389). It shows that aripiprazole treatment for first-episode schizophrenia can effectively control psychiatric symptoms with reliable efficacy and low incidence of adverse reactions,which is worthy of promotion and reference.
作者
衣斌
徐虹
YI Bin;XU Hong(Department of Seventh Therapy,Harbin First Specialized Hospital,Harbin 150056,China)
出处
《黑龙江科学》
2019年第6期58-59,共2页
Heilongjiang Science
关键词
阿立哌唑
首发精神分裂症
治疗作用
Aripiprazole
First-episode schizophrenia
Therapeutic effect
